Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
GLP-1 has been administered as a continuous infusion in type 2 diabetics with impressive insulin-sensitizing effects, reduced insulin resistance in skeletal muscle and adipose tissue, and improvements in insulin-mediated glucose uptake
Approval could come 6-12 months after US approval
Even before it added compounded GLP-1s to its portfolio, the company said in its 2023 fourth-quarter earnings call that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025
DOI: 10.1007/s00394-015-0922-1
US$ 29.59
US$ 27.31
US$ 28.10
US$ 29.14
US$ 22.29
US$ 25.02
